<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03531437</url>
  </required_header>
  <id_info>
    <org_study_id>656/2558 (Si726/2015)</org_study_id>
    <nct_id>NCT03531437</nct_id>
  </id_info>
  <brief_title>Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT</brief_title>
  <official_title>Comparison of Coagulation Profiles in Oral Contraceptive Pills Users Between 1.5 mg Estradiol/2.5 mg Nomegestrol Acetate (Zoely) and 15 mcg Ethinylestradiol/60 mcg Gestodene (Minidoz): A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of Zoely® and Minidoz® on hemostatic
      profiles
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      compare the effects of Zoely® and Minidoz® on hemostatic profiles : D-dimer, Antithrombin and
      fibrinogen
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    problem with recruiting participants
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">April 18, 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>D-dimer</measure>
    <time_frame>12 weeks</time_frame>
    <description>µg/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fibrinogen</measure>
    <time_frame>12 weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antithrombin III</measure>
    <time_frame>12 weeks</time_frame>
    <description>percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to access menstrual cycle and bleeding pattern, side effects of Zoely® and Minidoz®</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Contraception</condition>
  <condition>Hypercoagulability</condition>
  <arm_group>
    <arm_group_label>Zoely</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minidoz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5 mg estradiol and 2.5 mg nomegestrol acetate</intervention_name>
    <arm_group_label>Zoely</arm_group_label>
    <other_name>Zoely®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 µg ethinylestradiol and 60 µg gestodene</intervention_name>
    <arm_group_label>Minidoz</arm_group_label>
    <other_name>Minidoz®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman age 19-40 yr

          -  Normal uterus and both adnexae

          -  BMI &lt; 28.5 kg/m2

          -  Require contraception with COCs

        Exclusion Criteria:

          -  Pregnancy

          -  Postartum period within 6 wk

          -  Smoking

          -  BP ≥ 140/90 mmHg

          -  Contraindication to COCs : VTE, cerebrovascular disease, cardiovascular disease,
             migraine with aura, hepatitis, undiagnosed abnormal uterine bleeding, CA breast, DM
             with DN/DR

          -  use of liver-enzyme-inducing drugs, drugs affecting the haemostatic system

          -  Use contraceptive steroids within 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Nalinee Panichyawat</investigator_full_name>
    <investigator_title>Siriraj hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Gestodene</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

